Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹3,851 Cr
P/E Ratio
330.58
P/B Ratio
5.56
Industry P/E
51.44
Debt to Equity
0.78
ROE
-4.85 %
ROCE
-0.6 %
Div. Yield
0 %
Book Value
27.66
EPS
0.46
CFO
₹438.55 Cr
EBITDA
₹887.16 Cr
Net Profit
₹48.20 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sequent Scientific
| -12.41 | 6.45 | -12.88 | 25.90 | 3.86 | 15.95 | -- |
|
BSE Healthcare
| -4.95 | 1.92 | -0.50 | 24.13 | 20.27 | 23.08 | 9.93 |
|
BSE Small Cap
| -10.08 | 4.17 | -3.87 | 5.97 | 18.98 | 35.50 | 15.85 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Sequent Scientific
| 52.72 | 29.85 | -45.57 | -5.30 | 139.14 | 4.12 | -31.15 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2,202.50 | 9,009.27 | 74.22 | 12.96 | |
| 1,936.30 | 1,658.24 | 53.24 | 10.49 | |
| 1,181.30 | 736.30 | 22.56 | 12.02 | |
| 5,221.50 | 8,674.42 | 36.67 | 43.77 |
No Review & Analysis are available.
Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and... ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs & Pharmaceuticals Ltd. and changed its name to Sequent Scientific Limited in October 2009. The company was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited is a subsidiary of CA Harbor Investments. Read more
Incorporated
1985
Chairman
Kamal K Sharma
Managing Director
Rajaram Narayanan
Group
Sequent
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Sequent Scientific Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Sequent Scientific Ltd stood at ₹ 1,562 Cr as on 31-Dec-24
The share price of Sequent Scientific Ltd is ₹154.04 (NSE) and ₹153.85 (BSE) as of 24-Apr-2025 IST. Sequent Scientific Ltd has given a return of 3.86% in the last 3 years.
Sequent Scientific Ltd has a market capitalisation of ₹ 3,851 Cr as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Sequent Scientific Ltd is 5.56 times as on 24-Apr-2025, a 26% discount to its peers’ median range of 7.53 times.
The P/E ratio of Sequent Scientific Ltd is 330.58 times as on 24-Apr-2025, a 543% premium to its peers’ median range of 51.44 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sequent Scientific Ltd and enter the required number of quantities and click on buy to purchase the shares of Sequent Scientific Ltd.
Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs & Pharmaceuticals Ltd. and changed its name to Sequent Scientific Limited in October 2009. The company was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited is a subsidiary of CA Harbor Investments.
The promoter of Sequent Scientific Ltd is CA HARBOR INVESTMENTS. CA HARBOR INVESTMENTS owns 52.61 per cent of the total equity. The chairman of the company is Kamal K Sharma , and the managing director is Rajaram Narayanan..
There is no promoter pledging in Sequent Scientific Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
1,504
|
|
|
652
|
|
|
9,512
|
|
|
8,680
|
| Sequent Scientific Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
1.73
|
|
Operating margin(%)
|
5.36
|
|
Net Margin(%)
|
1.52
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Sequent Scientific Ltd was ₹12 Cr.
₹5.32
(
